The publisher explores Astellas’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (31 October 2020)
Model updates (31 January 2020)
Model updates (31 October 2019)
Model updates (14 August 2019)
Snapshot
- Overview - Astellas is forecast to grow revenue until 2026, at which point flagship product Xtandi will face the loss of patent exclusivity.
- Key themes - [1] Minimal short-term losses due to termination of sales and distribution agreement for Symbicort as well as decreases in vaccine revenues will be offset by its growing products [2] Astellas’s growth will be determined by new launched and pipeline assets such as Xospata, Evrenzo, and Evenity.
Model updates (31 October 2020)
- Xtandi forecast adjusted higher due to continued growth in prostate cancer
- Xospata forecast adjusted higher
- Celebrex forecast adjusted lower due to generic competition
- Sujanu forecast adjusted higher due to continued growth
- AT132 removed from forecast due to multiple patient deaths and clinical hold in ASPIRO trial.
Model updates (31 January 2020)
- Xospata forecast adjusted higher due to Europe launch
- Evenity forecast adjusted higher due to launch results
- Padcev EU and ROW launches expedited
- Roxadustat name changed to Evrenzo
- AT132 launch added due to closing of Audentes acquisition.
Model updates (31 October 2019)
- Xtandi revenue adjusted higher due to non-metastatic castration-resistant prostate cancer prescriptions exceeding forecast in the US
- Prograf forecast adjusted higher due to lower generic impact in the US
- Micardis forecast adjusted higher due to generic performance
- Roxadustat forecast adjusted for approval
- Symbicort forecast removed due to termination of sales and distribution agreement with KM Biologics
- Vaccines forecast adjusted lower due to company guidance.
Model updates (14 August 2019)
- AmBisome forecast adjusted higher due to company guidance
- Celebrex forecast adjusted higher due to company guidance
- Cresemba forecast adjusted lower for future patent expiry
- Mycamine forecast adjusted higher due to company guidance
- Xtandi forecast adjusted higher due to prostate cancer and overactive bladder treatment approvals
- Xospata forecast adjusted higher due to launch results
- Myrbetriq forecast adjusted lower due to company guidance
- Vesicare forecast adjusted lower due to generic competition
- Prograf forecast adjusted higher due to company guidance and expansion of clinical adoption in China
- Evenity forecast adjusted higher due to launch results
- Enfortumab vedotin forecast added
- Fezolinetant forecast added.
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview